EC 18 - Enzychem Lifesciences

Drug Profile

EC 18 - Enzychem Lifesciences

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator Enzychem Lifesciences Corporation
  • Class Antineoplastics; Chemoprotectants
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Macrophage stimulants; Neutrophil stimulants; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neutropenia
  • Preclinical Sepsis

Most Recent Events

  • 19 Jun 2017 Enzychem Lifesciences has patent protection for EC 18 worldwide
  • 19 Jun 2017 Phase-II clinical trials in Neutropenia (Chemotherapy-induced) in South Korea (PO)
  • 19 Jun 2017 Enzychem Lifesciences announces intention to submit IND application to the US FDA for Mucositis (Chemotherapy-induced) in June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top